OR WAIT 15 SECS
The company will expand its service offerings to include oligonucleotide API development and manufacture.
On July 1, 2016, CordenPharma announced that the company will expand into the oligonucleotide API development and manufacturing market. Corden has already begun to expand its Boulder, Colorado facility for the manufacture and development of oligonucleotide APIs. The expansion of the Colorado facility is expected to be complete by the end of 2016. This move will broaden the company’s service offerings, which currently include peptides, lipids, and carbohydrates for APIs and drug products.
“Based on the rich pipeline in the growing oligonucleotide field, this is a very logical move for CordenPharma within our current API and drug product manufacturing offerings,” Mimoun Ayoub, director Peptides, Lipids, Carbohydrates and Injectables Platforms, at CordenPharma International, said in a press statement. “The expansion into the oligonucleotide market is a synergistic complement to our outstanding experience in the manufacture of synthetic lipids, peptides, and carbohydrates, which are also used in oligonucleotide drug delivery.”